Health
FDA OKs new smoking cessation drug
NEWS IN BRIEF — Posted June 5, 2006
Anti-tobacco activists are cheering the Food and Drug Administration approval of varenicline tartrate, the first new smoking cessation drug in nearly a decade. This drug helps smokers give up the habit by reducing withdrawal symptoms and blocking the effect of nicotine on the brain. It will be marketed as Chantix by Pfizer and be accompanied by a support program intended to address behavioral issues associated with smoking.
"The announcement that the FDA has approved a new medication aimed at helping smokers quit is very welcome news," said Thomas J. Glynn, PhD, director of cancer science and trends at the American Cancer Society.
Studies have shown that this drug is more effective than placebo and other smoking cessation modalities currently on the market. Patients need to take it for three months and may take it for an additional three months to increase the chance that they will stay non-smokers over the long term. Side effects include nausea, headache, vomiting, flatulence, insomnia, abnormal dreams and a change in taste perception.
Note: This item originally appeared at http://www.ama-assn.org/amednews/2006/06/05/hlbf0605.htm.












